Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
2024 · The Lancet Regional Health - Europe · 56 citations
https://doi.org/10.1016/j.lanepe.2024.100862
I
Isabell Cordts
TUM Klinikum(DE)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
80
Papers
1.7K
Citations
22
h-index
37
i10-index
Isabell Cordts is an academic researcher from TUM Klinikum. The author has contributed to research in topics: Neurogenetic and Muscular Disorders Research & Amyotrophic Lateral Sclerosis Research & Genetic Neurodegenerative Diseases. The author has an h-index of 22, co-authored 68 publications.
ORCID: 0000-0002-2078-1997Papers by this author
worksImproved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study
2022 · Orphanet Journal of Rare Diseases · 39 citations
https://doi.org/10.1186/s13023-022-02547-8
The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research
2017 · Journal of Neurology · 28 citations
https://doi.org/10.1007/s00415-017-8483-2
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial
2024 · The Lancet Neurology · 25 citations
https://doi.org/10.1016/s1474-4422(24)00373-9
Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy
2020 · Scientific Reports · 16 citations
https://doi.org/10.1038/s41598-020-60240-x
Long-Term Dynamics of CSF and Serum Neurofilament Light Chain in Adult Patients With 5q Spinal Muscular Atrophy Treated With Nusinersen
2025 · Neurology · 10 citations
https://doi.org/10.1212/wnl.0000000000213371
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat